INTRODUCTION AND OBJECTIVES: Multiparametric prostate magnetic resonance imaging (mpMRI) utilizing the PI-RADS classification system attempts to identify clinically-significant [Gleason score (GS) 7 or higher] prostate cancer (PCa), with PI-RADS 1 or 2 typically corresponding to very low risk of clinically-significant PCa. In this study, we analyzed the clinicopathologic characteristics of patients undergoing prostate core biopsy (PBx) with PI-RADS 1 or 2 lesions.
METHODS: All patients at a single large academic institution who had at most PI-RAD 1 or 2 lesions on mpMRI between 1/1/15 and 6/30/16 and underwent pre-or post-MRI PBx were retrospectively identified. All cases of clinically-significant PCa were re-reviewed by study pathologists to confirm pathologic findings; clinicopathologic data from all other cases was obtained from pathology reports and electronic medical records.
RESULTS: 276 patients with PI-RADS 1 or 2 lesions were identified, of which 98 (35.5%) had either pre-(60) or post-MRI (38) inhouse PBx. Six (6.1%) patients showed GS7 PCa (3 pre-and 3 post-MRI), including 2 with GS4+3¼7 tumors. For the remaining patients, the most recent PBx findings included: GS6 PCa (22 pre-and 13 post-MRI); atypical glands (3 pre-and 2 post-MRI); high-grade prostatic intraepithelial neoplasia (5 pre-and 4 post-MRI); or, benign (27 pre-and 16 post-MRI). For patients with GS7 PCa, the median number of involved cores was 1 (range ¼ 1-3), the median number of total cores was 20 (range ¼ 12-30), the median % involvement of a single core was 12.5 (range ¼ 5-25), and the median % Gleason pattern 4 was 30 (range ¼ 5-90); types of Gleason pattern 4 included: poorly-formed glands only (4), cribriform glands only (1), or poorly-formed and cribriform glands (1). One GS7 tumor occurred in the post-radiation (XRT) setting, and one showed aberrant p63 expression; follow-up for patients with GS7 PCa included primary XRT (1), salvage XRT (1), and active surveillance (AS; 4). Nearly all patients (>90%) with GS6 PCa opted for AS; one patient underwent radical prostatectomy (pT2a GS6 PCa), and one patient was lost to follow-up.
CONCLUSIONS: The majority (58.2%) of patients with PI-RADS 1 or 2 lesions by mpMRI do not have detectable PCa on core biopsy, however, a small subset (6.1%) harbor GS7 PCa. Although long-term follow-up data are needed, PCa patients with PI-RADS 1 or 2 lesions by mpMRI appear to represent a very low-risk cohort that may be amenable to AS in the majority of cases.
Source of Funding: None

MP38-18 CLINICOPATHOLOGIC CHARACTERISTICS OF PATIENTS UNDERGOING PROSTATE CORE BIOPSY WITH HIGH-RISK (PI-RADS 5) LESIONS BY MULTIPARAMETRIC PROSTATE MAGNETIC RESONANCE IMAGING.
Joel Friedman*, Aaron Udager, Nicole Curci, Chandy Ellimoottil, Rohit Mehra, Scott Tomlins, Jeffrey Montgomery, John Wei, Matthew Davenport, Angela Wu, Lakshmi Kunju, Ann Arbor, MI INTRODUCTION AND OBJECTIVES: Multiparametric Prostate Magnetic Resonance Imaging (mpMRI) utilizes a PI-RADS classification system to identify clinically significant (Gleason score (GS) 7 or higher) prostate adenocarcinoma (PCa) with PI-RADS 5 lesions typically corresponding to a high-risk of clinically significant PCa.
METHODS: All patients who underwent mpMRI between 1/1/ 2015 and 6/30/2016 at a large academic institution were identified. Patients with one or more PI-RADS 5 lesions who underwent an ultrasound-MRI fusion PBx were retrospectively reviewed to assess for presence or absence of PCa, location (targeted vs. 12-core/non-targeted cores), GS, and percentage pattern 4 in GS 7 tumors.
RESULTS: 138 patients with PI-RADS 5 lesions {1 lesion (107), 2 lesions (27), 3 lesions (4)} were identified, of which 76 (55%) underwent an in-house MRI fusion PBx. In the targeted cores, 7 (9%) patients had no PCa and 69 (91%) patients showed PCa. In 7 patients without PCa (total 12 PI-RADS 5 lesions), the targeted cores showed extensive simple atrophy (2), florid adenosis (1), central zone histology (2), atypical small acinar proliferation (1), focal high-grade prostatic intraepithelial neoplasia (1), granulomatous inflammation (1), carcinoid (1), focal simple atrophy (2) and focal adenosis (1). Clinically significant PCa was noted in 79% (60/76) cases, {GS 3+4 (35), GS 4+3 (16) and GS 8-10 (9)}. In 7 (9%) patients with GS 7 or higher PCa, the highest GS was found in the non-targeted cores. The median % Gleason pattern 4 in GS 7 tumors was 30 (inter-quartile range ¼ 10-60). Of the remaining 62 (45%) patients who did not receive an MRI fusion PBx, 3 had saturation PBx and 27 had a radical prostatectomy (all show GS 7 or higher PCa); 9 received radiation and/or hormone therapy.
CONCLUSIONS: The vast majority of patients (79%) with PI-RADS 5 lesions showed GS 7 or higher PCa on targeted cores; however, a small subset (9%) showed no evidence of malignancy. The benign mimickers of PI-RADS 5 lesions include florid adenosis (1), granulomatous inflammation (1), carcinoid (1), central zone acini (2) and simple atrophy (2). PI-RADS 5 lesions can be biopsied for confirmation of clinically significant disease in the vast majority of cases or used to guide the patient's treatment towards more definitive therapies.
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MP38-19 MULTIPARAMETRIC MRI/ULTRASOUND FUSION BIOPSY IMPROVES BUT DOES NOT REPLACE STANDARD TEMPLATE BIOPSY FOR THE DETECTION OF PROSTATE CANCER
Nawar Hanna*, Matthew F. Wszolek, Francisco J. Gelpi-Hammerschmidt, Keyan Salari, Mukesh Harisinghani, Douglas M. Dahl, Micheal L. Blute, Adam S. Feldman, Boston, MA INTRODUCTION AND OBJECTIVES: There exists a growing debate as to whether mp-MRI targeted biopsy alone without standard template is sufficient for evaluation of patients with suspicion of prostate cancer. We investigate and describe our experience with fusion biopsy.
METHODS: We retrospectively reviewed medical charts of patients undergoing fusion transrectal US-guided biopsy from July 2014 through February 2016. Patients eligible for fusion biopsy had identifiable lesions on mp-MRI compatible to the fusion biopsy system. Each lesion was graded according to the Prostate Imaging Reporting and Data System version 2 (PIRADSv2) by a radiologist. The fusion biopsy procedure included a minimum of 2 core biopsies for each target lesion and a standard 12 core template biopsy. Clinically significant disease was defined as Gleason Score 7 or higher adenocarcinoma of the prostate.
RESULTS: A total of 255 patients with a mp-MRI-identified lesion underwent fusion and standard template biopsy. Indications included elevated PSA without a prior biopsy (11.4%), rising PSA with a prior negative biopsy (52.4%), active surveillance for prostate cancer (33.3%) and isolated abnormal digital rectal exam (2.7%). Pathologic results from the fusion-targeted biopsy were compared to those from the concomitantly performed standard template biopsies (Table 1) . Of patients with PIRADSv2 4 or 5 lesions (n¼145), 40.0% had no cancer, Vol. 197, No. 4S, Supplement, Saturday, May 13, 2017 THE JOURNAL OF UROLOGY â e491
